Double lettings boost for Liverpool Science Park

TWO new laboratory lettings at Liverpool Science Park have further boosted the city region’s thriving £1.7bn life sciences sector and added to the diverse mix of technology tenants.

Lab space at Liverpool Science Park’s new £8m wing of Innovation Centre 1 (ic1) is now more than 70% full following the addition of two new bioscience businesses – Nano Biosols and Gemini Biosciences.

With close links to the University of Liverpool, both companies are developing products and services to support biomedical and life sciences research.

The double move means that eight out of 11 of the laboratories in Liverpool Science Park’s new wing on Mount Pleasant are now taken.

The take up of labs also spans knowledge rich technology businesses, advanced manufacturing and chemistry.

Chris Musson, chief executive of Liverpool Science Park, which celebrates its 10th anniversary this year, said: “The extension to the ic1 building was built speculatively in response to the growing demand for lab space in the city from a variety of technologies – basically any business needing to operate out of a clean, sterile environment.

“We’re therefore delighted to see such as positive take up for the lab space and to see such a unique mix of businesses enjoying the facilities.

“These two new businesses are young, bright and incredibly knowledgeable in their fields of life sciences research and so it’s a pleasure to welcome them to the diverse mix of tenants here at the park.”

Nano Biosols was founded by Adrian Walsh after he received £100,000 investment through The North West Fund for Biomedical, administered by fellow science park tenant, SPARK Impact.

Walsh had previously worked at the University of Liverpool for a number of years to develop the gold nanoparticle technology for use in medicines before deciding to pursue his own commercial business.

Walsh said: “Nanomedicine is a growing sector and I’m really pleased with how successful the transition from an academic setting to a business environment has gone so far.

Gemini Biosciences launched this month and plans to develop and commercialise life sciences and biomedical research products and technologies to scientists working at universities, research institutes biotech and pharmaceutical companies.